MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
Defence, Cdn Nuclear Laboratories expand work program
Netramark closes $3.11M first tranche of financing
Cipher Pharmaceuticals gets Health Canada NDS review
LSL obtains FDA certification for ophthalmic ointments
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
NetraMark Closes First Tranche of Private Placement
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba(TM) (Spinosad)
Ventripoint Issues Shares for Debt Settlement and Awards Option Grants
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
Innocan Pharma to list on NYSE American